Osteoporos Sarcopenia.
2019 Jun;5(2):57-61. 10.1016/j.afos.2019.06.001.
Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
- Affiliations
-
- 1Center of Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Matsumoto, Japan.
- 2Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan. yxn14@aol.jp
- 3Department of Orthopedic Surgery, North Alps Medical Center Azumi Hospital, Ikeda, Japan.
- 4Koiwai Orthopedic Clinic, Komoro, Japan.
- 5Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan.
- 6Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Shiojiri, Japan.
- KMID: 2463607
- DOI: http://doi.org/10.1016/j.afos.2019.06.001
Abstract
OBJECTIVES
We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor response to BPs.
METHODS
Forty-two post-menopausal patients with primary osteoporosis and low lumbar BMD (L-BMD) and/or bilateral total hip BMD (H-BMD) values receiving long-term BP treatment were prospectively enrolled. Serum bone alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-terminal telopeptide of type I collagen (NTX) was assessed as a bone resorption marker. L-BMD, H-BMD, and femoral neck BMD (N-BMD) were recorded before, at the commencement of, and during ELD administration.
RESULTS
BAP and urinary NTX were significantly decreased by BP therapy prior to ELD. ELD addition further significantly decreased the bone turnover markers (both p < 0.01). The mean L-BMD increase rate was 0.2% (p = 0.81) from 2 to 1 years before ELD administration, −0.7% (p = 0.30) during the year before ELD, and 2.9% (p < 0.01) during 1 year of ELD. Similar findings were observed for the mean increase rate of H-BMD, with values of 0.2% (p = 0.55), −0.7% (p < 0.01), and 1.2% (p < 0.01), respectively. The mean N-BMD increase rate was significantly increased after ELD administration (1.1%, p = 0.03) despite no gains by BP therapy alone.
CONCLUSIONS
This study suggests that ELD addition may be useful for osteoporotic patients exhibiting a diminished long-term BP therapy response.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Insufficiency Fracture of Ipsilateral Femur Neck in Patient Treated with Long Term Bisphosphonate Treatment: A Case Report
- Bisphosphonate: An Invaluable Medication or Abandoned Acid?
- A Case Report of Long-Term Bisphosphonate Therapy and Atypical Stress Fracture of Bilateral Femur
- Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate
- Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
